ArticleFrontiers in medicine2026
Nursing care of an elderly patient with toxic epidermal necrolysis: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxic epidermal necrolysis (TEN) is a rare, life-threatening mucocutaneous disorder, and its occurrence in elderly patients with compromised immunity and multiple comorbidities poses significant challenges to nursing care and prognosis. This paper summarizes the ICU nursing experience of an 84-year-old female patient with TEN presumably induced by parecoxib injection. The patient presented with 55% body surface area (BSA) skin involvement, combined with bedridden status due to fracture and electrolyte disturbances, with an expected mortality rate of 30-50%. An individualized nursing plan was formulated through multidisciplinary collaboration. Clinically, skin wound care was the cornerstone of management, incorporating refined, stage-specific interventions during the blister exudation, crusting, and healing phases, with yellow light irradiation and epidermal growth factor applied throughout all phases to promote wound healing. Targeted nursing measures were applied to vulnerable mucous membranes, particularly the oral cavity, eyes, and perianal region, including occlusive therapy and fecal diversion using ostomy bags to reduce local irritation. A midline catheter was prioritized, and an innovative adhesive-free dressing fixation strategy was adopted to ensure the safety of intravenous access. Full-process protective isolation and strict aseptic techniques were implemented to strengthen infection prevention and control. Meanwhile, medication nursing for immunomodulation, anti-inflammatory therapy, and symptomatic supportive care was delivered in accordance with the S3 Guideline: Diagnosis and Treatment of Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) developed by the German Dermatological Society (Deutsche Dermatologische Gesellschaft, DDG). Following 17 days of systematic nursing care, the patient's wounds achieved nearly complete epithelialization, with no new blisters or exudation observed. Infection markers were significantly reduced, and the patient was successfully transferred to a rehabilitation ward. Her recovery duration was shorter than the average for similar patients, and no severe ocular complications developed. This case demonstrates that a comprehensive nursing strategy incorporating staged wound care, multidimensional mucosal protection, individualized intravenous access management, and full-process infection control can effectively reduce complication risks, accelerate wound healing, and improve outcomes in elderly patients with severe TEN, providing a reference for clinical nursing practice in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.